By Stephen Nakrosis
Avita Medical said the U.S. Food and Drug Administration has approved the company's premarket approval supplement for Recell Go mini, a system to treat smaller wounds.
The Recell Go mini is a line extension of the Recall Go system, and is designed as a treatment for wounds up to 480 square centimeters. The standard Recall Go system treats an area of 1,920 square centimeters, the company said.
Avita said the Recell Go mini can serve as an entry point for clinicians who are unfamiliar with the system, and will allow broader accessibility and use in trauma and burn centers.
Roll out of the Recell Go mini will begin during the first quarter of 2025, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 23, 2024 16:26 ET (21:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.